Altimmune, Inc. (ALT) Cash Flow Statement
Altimmune, Inc. (ALT) generated -$76.5M of operating cash flow over the twelve months to 2026-06-30, spent $54000 on capital expenditure and had free cash flow of -$76.6M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ALTAltimmune, Inc.Follow ALT — free
—
Price chart with a free account
- Market cap
- 412.4M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
| Line | FY2011 Dec 11 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2021 Dec 21 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -7.8 | -20.2 | -9.4 | -9.6 | -78.2 | -75.8 | -79.8 | -67.5 | -76.5 | |
| Capital expenditure | 0.1 | 0.1 | 1.0 | 0.0 | 12.1 | 0.0 | — | 0.0 | -0.1 | |
| Free cash flow | -7.9 | -20.3 | -10.4 | -9.6 | -90.4 | -75.9 | — | -67.5 | -76.6 | |
| Stock-based compensation | 2.6 | 1.4 | 0.8 | 1.3 | 5.5 | 10.6 | 14.4 | 16.1 | — |
USD millions · SEC XBRL
Altimmune, Inc. — questions
- What is Altimmune, Inc.'s operating cash flow?
- -$76.5M over the twelve months to 2026-06-30.
- How much does Altimmune, Inc. spend on capital expenditure?
- $54000 over the twelve months to 2026-06-30.
- What is Altimmune, Inc.'s free cash flow?
- -$76.6M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Altimmune, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.